Blue Cross Blue Shield of Alabama announced it has lowered copays for Novolog insulin, Azmanex inhalers, Alnuity Ellipta inhalers and QVAR Redihaler. The company said it is working to ease members' financial burden and make its products more accessible at lower prices.

According to BCBS Alabama, the following adjustments took effect on April 1, 2024:

Insulin

To keep net costs low, the manufacturer of Novolog insulin has recently reduced the price of its insulin product and has partnered with Blue Cross through the insurer's pharmacy benefits manager (PBM), Prime Therapeutics. Through this partnership, Blue Cross will reduce copays for Novolog insulin to the lowest possible levels and pass those savings directly to members.

Inhalers

GlaxoSmithKline has discontinued production of the Flovent HFA inhaler and has also launched an approved generic. In order to keep inhaler costs as low as possible for Blue Cross members, the company has reduced the cost-sharing for alternatives such as the Asmanex inhaler, the Alnuity Ellipta inhaler and the QVAR Ladyhaler.

Austin Shipley is a staff writer for Yellow Hammer News.